Novo Nordisk's Saxenda Shows Promise in Tackling Childhood Obesity

Novo Nordisk's Saxenda, a weight-loss drug, significantly reduced BMI in children aged 6 to under 12 in a 56-week trial. The study, presented at a medical meeting, showed improvements in blood pressure and glucose control. Novo has applied for regulatory approval to expand Saxenda's use to this age group.

In a groundbreaking 56-week trial, Novo Nordisk's weight-loss drug Saxenda has demonstrated significant potential in reducing body mass index (BMI) among children aged 6 to under 12. The trial results were unveiled at a recent medical meeting, showcasing a 7.4% reduction in BMI and significant improvements in blood pressure and blood glucose control.

This study, the first to assess Saxenda's safety and efficacy in young children, met its primary endpoint of BMI reduction. Saxenda, known chemically as liraglutide, was earlier approved for adolescents in 2020 and adults in 2014. The drugmaker has now sought regulatory approval in the U.S. and Europe to include younger children in its usage guidelines.

Experts at the European Association for the Study of Diabetes meeting in Madrid and published findings in the New England Journal of Medicine highlighted the dire need for effective pediatric obesity treatments. Professor Claudia Fox of the University of Minnesota emphasized the new hope Saxenda provides for healthier, more productive lives for obese children.

(With inputs from agencies.)